Related Experiment Video
Updated: Sep 15, 2026

Flow Cytometric Analysis of Apoptotic Biomarkers in Actinomycin D-Treated SiHa Cervical Cancer Cells
Published on: August 26, 2021
The carcinolytic effect of actinomycin C; a report of clinical studies
Abstract:
Actinomycin C was administered to 35 patients with a variety of malignant states. There was no evidence of any toxic reaction. Of 11 patients with Hodgkins disease, four had brief objective remission ranging from two to four months. Individual patients with chronic myelogenous leukemia, multiple myeloma and neuroblastoma had short periods of clinical improvement. The usefulness of actinomycin C appears to be limited. It may best be used in instances of Hodgkin's disease where pancytopenia prevents the use of other agents.
Related Concept Videos
Introduction to Actin
Actin Filament Depolymerization
In F-actin, the ADF/cofilin proteins...
Actin Polymerization and Cell Motility
Actin cytoskeleton dynamics can produce pushing, pulling, and resistance forces that help the cell to migrate.
The Role of Actin and Myosin in Non-muscle Cells

